Pharmacokinetic profile of tamsulosin OCAS

BJU International

Volumn 98, Issue SUPPL. 2, 2006, Pages 9-12

  Chapple, Christopher R ^a   Chartier Kastler, Emmanuel ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

BPH; LUTS; OCAS; Oral controlled absorption system; Pharmacokinetic; Scintigraphy; Tamsulosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; OCAS; TAMSULOSIN;

BLOOD SAMPLING; CLINICAL TRIAL; COLON ABSORPTION; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HALF LIFE; DRUG RELEASE; FOOD INTAKE; GAMMA SCINTIGRAPHY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRANSIT; HUMAN; NOCTURIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; TABLET FORMULATION; URETHRA DISEASE; URINARY TRACT DISEASE;

EID: 33748858152     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06494.x     Document Type: Review

References (20)

1. O'Leary MP. Quality of life and α-blocker therapy: an important consideration for both the patient and the physician. Urology 2002; 59 (Suppl. 2): 7-11
2. Coffey DS. Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol 1998; 81 (Suppl. 1): 1-5
3. Souverein PC, Erkens JA, de la Rosette JJ, Leufkens HG, Herings RM. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 2003; 43: 528-34
4. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081-8
5. Anderson KE, Chapple C, El Hilali et al. Benign prostatic hyperplasia. In Chatelain C, Denis L, Foo KT, Khoury S, McConnell J eds, Proceedings of the Fifth International Consultation on Benign Prostatic Hyperplasia (BPH). Fifth International Consultation on Benign Prostatic Hyperplasia (BPH), June 25-28, 2000 Paris. Plymouth: UK Health Publications, 2001: 1-535
6. 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995; 76: 325-36
7. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19: 135-61
8. Abrams P. Nocturia: the major problem in patients with lower urniary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol Suppl 2005; 3: 8-16
9. Fix JA, Sako K, Sawada T. Controlled-release oral delivery systems. In Park K, Mrsny RJ eds, Controlled drug delivery: designed technologies for the future, Chapt 2. Oxford: Oxford University Press, 2000; 14-24
10. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-87
11. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37: 306-13
12. McKeage K, Plosker GL. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633-53
13. Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®). Eur Urol Suppl 2005; 4: 15-24
14. Sako K, Mizumoto T, Kajiyama A, Ohmura T. Influence of physical factors in gastrointestinal tract on acetaminophen release from controlled-release tablets in fasted dogs. Int J Pharm 1996; 137: 225-32
15. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62: 135-67
16. 1-adrenoceptor antagonism of tamsulosin in oral controlled absorption system (OCAS) and modified release (MR) formulations. Eur Urol Suppl 2005; 4: 45-52
17. Michel MC, Korstanje C, Krauwinkel W, Shear M, Davies J, Quartel A. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl 2005; 4: 53-60
18. Michel MC, Chapple CR. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS®) and alfuzosin prolonged release (XL). Eur Urol 2006; 49: 501-9
19. Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 2005; 4: 61-8
20. Stevens NHE. Behaviour and transit of tamsulosin Oral Controlled Absorption System (OCAS®) in the gastrointestinal tract. Curr Med Res Opin 2006; submitted